STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen…
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended…
3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental…
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on…
"From Healthcare and Life Sciences to Oil & Gas and Diagnostics, BCC Research Highlights How AI is Transforming Industries, Enhancing…
Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of…
FORT LEE, NJ, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on…
- GCCL's "One-Stop Lab Solution" sets the industry benchmark with unmatched competitiveness and a dedication to global excellence. - Continuing…
Published in Journal of American Medical Association (JAMA) Dermatology, Sibel's advanced wearable sensor coupled with biofeedback led to a 40% decrease…